Insider Buying: Oruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Acquires 88,794 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) major shareholder Venrock Healthcare Capital Par purchased 88,794 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The stock was bought at an average cost of $11.44 per share, with a total value of $1,015,803.36. Following the completion of the purchase, the insider now owns 4,148,428 shares of the company's stock, valued at $47,458,016.32. This represents a 2.19 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Wednesday, February 12th, Venrock Healthcare Capital Par purchased 8,971 shares of Oruka Therapeutics stock. The shares were purchased at an average price of $11.86 per share, for a total transaction of $106,396.06.
• On Monday, February 10th, Venrock Healthcare Capital Par bought 574 shares of Oruka Therapeutics stock. The stock was bought at an average price of $10.90 per share, for a total transaction of $6,256.60.

Oruka Therapeutics Stock Performance

ORKA traded down $0.24 during trading on Monday, hitting $9.91. The company's stock had a trading volume of 198,626 shares, compared to its average volume of 287,831. The stock has a market cap of $346.84 million, a price-to-earnings ratio of -1.58 and a beta of 0.77. Oruka Therapeutics, Inc. has a one year low of $9.53 and a one year high of $53.88. The stock has a 50 day moving average price of $14.07.

Remove Ads

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on ORKA shares. HC Wainwright restated a "buy" rating and issued a $45.00 target price on shares of Oruka Therapeutics in a report on Friday, February 7th. Wolfe Research started coverage on shares of Oruka Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 target price on the stock. Finally, Wedbush restated an "outperform" rating and issued a $40.00 target price on shares of Oruka Therapeutics in a report on Tuesday, November 19th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $39.86.

Institutional Trading of Oruka Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. bought a new stake in shares of Oruka Therapeutics during the 4th quarter valued at $54,000. AlphaCentric Advisors LLC purchased a new stake in Oruka Therapeutics in the 4th quarter worth $119,000. China Universal Asset Management Co. Ltd. purchased a new stake in Oruka Therapeutics in the 4th quarter worth $144,000. Squarepoint Ops LLC purchased a new stake in Oruka Therapeutics in the 4th quarter worth $236,000. Finally, Geode Capital Management LLC purchased a new stake in Oruka Therapeutics in the 3rd quarter worth $343,000. 56.44% of the stock is currently owned by institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.